B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Terns Pharmaceuticals, Inc.

< Previous 1 2 Next >
Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Announces Pricing of Upsized $150.15 Million Public Offering
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Announces Proposed Public Offering
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Announces Leadership Changes
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers TERN
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.